Kura Oncology, Inc. (KURA)

NMS – Цена в реальном времени. Валюта: USD

9.68

+0.17 (1.79%)

При закрытии: May 12, 2026, 4:00 PM EDT

9.23

-0.45 (-4.63%)

После закрытия: May 12, 2026, 7:55 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Kura Oncology, Inc. (KURA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kura Oncology, Inc. (KURA)

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Search stocks

Kura Oncology, Inc. (KURA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kura Oncology, Inc. (KURA)

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML